These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 26264858)

  • 21. Cognitive impairment in a population-based study of patients with multiple sclerosis: differences between late relapsing-remitting, secondary progressive and primary progressive multiple sclerosis.
    Planche V; Gibelin M; Cregut D; Pereira B; Clavelou P
    Eur J Neurol; 2016 Feb; 23(2):282-9. PubMed ID: 25903918
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A low vitamin D status at diagnosis is associated with an early conversion to secondary progressive multiple sclerosis.
    Muris AH; Rolf L; Broen K; Hupperts R; Damoiseaux J; Smolders J
    J Steroid Biochem Mol Biol; 2016 Nov; 164():254-257. PubMed ID: 26598277
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association of cerebrospinal fluid levels of lateral olfactory tract usher substance (LOTUS) with disease activity in multiple sclerosis.
    Takahashi K; Kurihara Y; Suzuki Y; Goshima Y; Tanaka F; Takei K
    JAMA Neurol; 2015 Feb; 72(2):176-9. PubMed ID: 25437093
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumor necrosis factor-alfa and interleukin-4 in cerbrospinal fluid and plasma in different clinical forms of multiple sclerosis.
    Obradović D; Kataranovski M; Dincić E; Obradović S; Colić M
    Vojnosanit Pregl; 2012 Feb; 69(2):151-6. PubMed ID: 22500369
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differences in retinal nerve fiber layer atrophy between multiple sclerosis subtypes.
    Costello F; Hodge W; Pan YI; Freedman M; DeMeulemeester C
    J Neurol Sci; 2009 Jun; 281(1-2):74-9. PubMed ID: 19303605
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pain Intensity and Pain Interference in People With Progressive Multiple Sclerosis Compared With People With Relapsing-Remitting Multiple Sclerosis.
    Knowles LM; Phillips KM; Herring TE; Alschuler KN; Jensen MP; Turner AP; Ehde DM
    Arch Phys Med Rehabil; 2021 Oct; 102(10):1959-1964. PubMed ID: 34048792
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Balance performance in three forms of multiple sclerosis.
    Soyuer F; Mirza M; Erkorkmaz U
    Neurol Res; 2006 Jul; 28(5):555-62. PubMed ID: 16808889
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Shape analysis of the corpus callosum and cerebellum in female MS patients with different clinical phenotypes.
    Sigirli D; Ercan I; Ozdemir ST; Taskapilioglu O; Hakyemez B; Turan OF
    Anat Rec (Hoboken); 2012 Jul; 295(7):1202-11. PubMed ID: 22585536
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Injury to white matter tracts in relapsing-remitting multiple sclerosis: A possible therapeutic window within the first 5 years from onset using diffusion-tensor imaging tract-based spatial statistics.
    Asaf A; Evan S; Anat A
    Neuroimage Clin; 2015; 8():261-6. PubMed ID: 26106550
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cortical dysfunction underlies disability in multiple sclerosis.
    Vucic S; Burke T; Lenton K; Ramanathan S; Gomes L; Yannikas C; Kiernan MC
    Mult Scler; 2012 Apr; 18(4):425-32. PubMed ID: 21965421
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of endogenous antiradical protective system in multiple sclerosis.
    Davitashvili D; Beridze M; Shakarishvili R; Kiziria M; Sanikidze T
    Georgian Med News; 2012 Apr; (205):11-9. PubMed ID: 22665726
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SIGLEC1 and SIGLEC7 expression in circulating monocytes of patients with multiple sclerosis.
    Malhotra S; Castilló J; Bustamante M; Vidal-Jordana A; Castro Z; Montalban X; Comabella M
    Mult Scler; 2013 Apr; 19(5):524-31. PubMed ID: 22933622
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Progressive multiple sclerosis: The treatment gap.
    Humphries C
    Nature; 2012 Apr; 484(7393):S10. PubMed ID: 22509511
    [No Abstract]   [Full Text] [Related]  

  • 34. Gene expression analysis of relapsing-remitting, primary progressive and secondary progressive multiple sclerosis.
    Ratzer R; Søndergaard HB; Christensen JR; Börnsen L; Borup R; Sørensen PS; Sellebjerg F
    Mult Scler; 2013 Dec; 19(14):1841-8. PubMed ID: 24085340
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Natural history of secondary-progressive multiple sclerosis.
    Tremlett H; Yinshan Zhao ; Devonshire V
    Mult Scler; 2008 Apr; 14(3):314-24. PubMed ID: 18208898
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cognitive reserve in secondary progressive multiple sclerosis.
    Sumowski JF; Chiaravalloti N; Leavitt VM; Deluca J
    Mult Scler; 2012 Oct; 18(10):1454-8. PubMed ID: 22389412
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment effects of immunomodulatory therapies at different stages of multiple sclerosis in short-term trials.
    Bates D
    Neurology; 2011 Jan; 76(1 Suppl 1):S14-25. PubMed ID: 21205678
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum homocysteine levels in relation to clinical progression in multiple sclerosis.
    Teunissen CE; Killestein J; Kragt JJ; Polman CH; Dijkstra CD; Blom HJ
    J Neurol Neurosurg Psychiatry; 2008 Dec; 79(12):1349-53. PubMed ID: 18676406
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association of a Marker of N-Acetylglucosamine With Progressive Multiple Sclerosis and Neurodegeneration.
    Brandt AU; Sy M; Bellmann-Strobl J; Newton BL; Pawling J; Zimmermann HG; Yu Z; Chien C; Dörr J; Wuerfel JT; Dennis JW; Paul F; Demetriou M
    JAMA Neurol; 2021 Jul; 78(7):842-852. PubMed ID: 33970182
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The transitional phase of multiple sclerosis: Characterization and conceptual framework.
    Kleiter I; Ayzenberg I; Havla J; Lukas C; Penner IK; Stadelmann C; Linker RA
    Mult Scler Relat Disord; 2020 Sep; 44():102242. PubMed ID: 32535501
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.